Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Baxter
Queensland Health
Cipla
Boehringer Ingelheim
Citi
McKesson
McKinsey
Johnson and Johnson

Generated: September 19, 2018

DrugPatentWatch Database Preview

Bismuth subcitrate potassium; metronidazole; tetracycline - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for bismuth subcitrate potassium; metronidazole; tetracycline and what is the scope of bismuth subcitrate potassium; metronidazole; tetracycline freedom to operate?

Bismuth subcitrate potassium; metronidazole; tetracycline is the generic ingredient in one branded drug marketed by Allergan Sales Llc and is included in one NDA. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are twenty-one drug master file entries for bismuth subcitrate potassium; metronidazole; tetracycline. One supplier is listed for this compound.

Summary for bismuth subcitrate potassium; metronidazole; tetracycline
Pharmacology for bismuth subcitrate potassium; metronidazole; tetracycline

US Patents and Regulatory Information for bismuth subcitrate potassium; metronidazole; tetracycline

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for bismuth subcitrate potassium; metronidazole; tetracycline

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Baxter
Queensland Health
Cipla
Boehringer Ingelheim
Citi
McKesson
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.